UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the month of August 2021
Commission
File Number 001-38716
GAMIDA
CELL LTD.
(Translation
of registrant’s name into English)
5
Nahum Heftsadie Street
Givaat
Shaul, Jerusalem 91340 Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On
August 11, 2021, Gamida Cell Ltd. (the “Company”) issued a press release, a copy of which is furnished as Exhibit 99.1 to
this Form 6-K.
The
information included under the captions “Omidubicel: Advanced Cell Therapy,” “GDA-201: NAM-Enabled NK
Immunotherapy,” “NAM-Enabled NK Cell Pipeline Expansion,” “Corporate,” “Second Quarter 2021
Financial Results” and “Expected 2021 Developments and Milestones” of the press release, as well as the Unaudited
Interim Consolidated Financial Statements as of June 30, 2021 attached hereto as Exhibit
99.2 to this Form 6-K, are hereby incorporated
by reference into the Company’s Registration Statement on Form F-3 (File No. 333-234701), the Registration Statement on Form
F-3 (File No. 333-253720) and the Registration Statement on Form S-8 (File No. 333-238115).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
GAMIDA
CELL LTD.
|
|
|
|
|
|
August
12, 2021
|
By:
|
/s/
Shai Lankry
|
|
|
|
Shai
Lankry
|
|
|
|
Chief
Financial Officer
|
2
false
--12-31
Q2
2021-06-30
0001600847